Tetra Bio-Pharma

Tetra Bio-Pharma earns a Neutral rating at a 43.4 composite score, with conviction at 2/5. The regulatory pillar provides the principal support at 58, driven by Canada’s 80 jurisdiction posture and an 80 enforcement subscore reflecting zero enforcement hits. Fundamentals contribute 41, supported by respectable revenue-growth and operating-margin subscores but constrained by the lowest market-cap tier and a 15 cash-runway subscore. The market pillar adds 40 despite unavailable institutional pricing, while editorial contributes 30 as CIN newsroom coverage recorded no newsroom or brief activity. The resulting profile sits squarely in the Neutral band: regulatory structure offsets weak financial capacity, limited price discovery, and sparse editorial visibility.

Underlying fundamentals remain stretched. Year-over-year revenue growth was nil, and the operating margin also registered nil, preventing evidence of commercial momentum or operating leverage. Net income was a loss of approximately $16.9 million, while EBITDA was negative by roughly $12.2 million; those figures reinforce the stated stretched financial condition rather than signaling balance-sheet repair. A cash-burn ratio near 7 and a market capitalization of about $1.7 million further depress the fundamental assessment. Filing cadence is another constraint: no latest filing date was available, and no regulatory events appeared across either the 90-day or 180-day windows. That absence produced a cadence subscore of 25, even as jurisdiction and enforcement factors remained comparatively strong. The assessment draws on primary regulatory filings, institutional pricing feeds, licensed fundamentals data, and CIN newsroom coverage.

The forward catalyst rests on the regulatory pillar because it already carries the highest score and the strongest identifiable drivers. A fresh primary regulatory filing that restores visible cadence would add current disclosure to Canada’s favorable jurisdiction posture and the clean enforcement record, strengthening the only pillar above the composite score. Such a filing also enables reassessment of revenue formation, operating economics, cash consumption, and the continuing net loss without treating negative EBITDA as evidence of financial recovery. The single most important signal to watch is the appearance of a timely primary regulatory filing that improves the 25 cadence subscore.